Security Snapshot

Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) Institutional Ownership

CUSIP: 45720N103

13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

138

Shares (Excl. Options)

12,777,955

Price

$79.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
INBX on Nasdaq
Shares outstanding
14,560,641
Price per share
$67.23
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
12,777,955
Total reported value
$1,009,450,047
% of total 13F portfolios
0%
Share change
+2,191,004
Value change
+$184,334,509
Number of holders
138
Price from insider filings
$67.23
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45720N103.
  • 138 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 138 to 12 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,009,450,047 to $1,464,922.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 138 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 45720N103?
CUSIP 45720N103 identifies INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VIKING GLOBAL INVESTORS LP 10% $106,593,674 1,454,608 VIKING GLOBAL INVESTORS LP 31 Dec 2025
MORGAN STANLEY 7.9% $84,668,884 1,155,416 Morgan Stanley 31 Dec 2025
Kayyem Jon Faiz 7.9% $13,765,571 1,149,046 Jon Faiz Kayyem 03 Jun 2024
Lappe Mark 6.4% $11,086,448 925,413 Mark Lappe 12 Sep 2024
BlackRock, Inc. 5.3% +12% $60,682,270 +$6,933,198 768,130 +13% BlackRock, Inc. 31 Dec 2025

As of 31 Dec 2025, 138 institutional investors reported holding 12,777,955 shares of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX). This represents 88% of the company’s total 14,560,641 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
PERCEPTIVE ADVISORS LLC 10% 1,452,707 +9.4% 2.1% $114,763,853
VIKING GLOBAL INVESTORS LP 9.9% 1,437,705 -20% 0.3% $113,578,695
MORGAN STANLEY 8% 1,167,728 +164% 0.01% $92,250,538
Sanofi 8% 1,157,926 0% 29% $91,476,154
HighTower Advisors, LLC 6% 870,507 -0.14% 0.08% $68,770,053
BlackRock, Inc. 5.3% 777,383 +14% 0% $61,413,257
VANGUARD GROUP INC 4.3% 623,084 +4.7% 0% $49,223,636
Sofinnova Investments, Inc. 3.1% 454,657 +3.3% 1.5% $35,917,903
Capital Research Global Investors 2.9% 421,575 0.01% $33,304,425
STATE STREET CORP 2.6% 374,961 +84% 0% $29,621,919
Caligan Partners LP 2.2% 323,565 +37% 2.3% $25,561,635
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2% 297,116 0.03% $23,472,164
MILLENNIUM MANAGEMENT LLC 1.9% 275,917 -7.4% 0.02% $21,797,443
PFM Health Sciences, LP 1.8% 265,517 +11% 2.1% $20,975,843
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.8% 264,000 0.04% $20,856,000
GEODE CAPITAL MANAGEMENT, LLC 1.6% 226,009 +1.8% 0% $17,858,743
Schonfeld Strategic Advisors LLC 1.5% 214,725 +120% 0.09% $16,963,275
Woodline Partners LP 0.96% 139,479 -59% 0.04% $11,018,841
NORGES BANK 0.92% 133,300 0% $10,530,700
D. E. Shaw & Co., Inc. 0.84% 122,101 +957% 0.01% $9,645,979
Invesco Ltd. 0.77% 112,396 +540% 0% $8,879,284
CDC Financial, Inc. 0.76% 110,810 0% 8.1% $8,753,990
GOLDMAN SACHS GROUP INC 0.69% 100,617 +287% 0% $7,948,743
BOOTHBAY FUND MANAGEMENT, LLC 0.63% 92,009 +17% 0.19% $7,268,711
NORTHERN TRUST CORP 0.61% 88,509 -4.5% 0% $6,992,211

Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 21,797 $1,464,922 -$1,131,183 $67.23 12
2025 Q4 12,777,955 $1,009,450,047 +$184,334,509 $79.00 138
2025 Q3 10,497,334 $353,550,847 +$6,764,063 $33.68 101
2025 Q2 10,435,616 $148,917,132 -$5,468,523 $14.27 87
2025 Q1 10,790,279 $150,950,613 -$5,227,676 $13.99 92
2024 Q4 11,165,626 $171,927,470 +$10,221,839 $15.40 101
2024 Q3 8,897,409 $139,328,871 -$10,813,194 $15.66 95
2024 Q2 9,650,613 $136,747,433 +$136,582,849 $14.17 86